This inventor holds 2 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 2010-2012.
Company Filing History:
Years Active: 2010-2012
Title: Justin K Weaver: Innovator in Bioconversion Technologies
Introduction
Justin K Weaver is a notable inventor based in Clinton, IN (US). He has made significant contributions to the field of bioconversion, particularly in the development of methods for converting aliphatic dinitriles into useful cyanocarboxylic acids. With a total of 2 patents, Weaver's work has implications for the treatment of various cerebral diseases.
Latest Patents
Weaver's latest patents focus on the stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids. The present invention is directed to a regio- and stereoselective bioconversion of selected aliphatic dinitriles into corresponding cyanocarboxylic acids. More particularly, the invention provides methods for the conversion of 2-isobutyl-succinonitrile into (S)-3 cyano-5-methylhexanoic acid. This compound serves as a useful intermediate in the synthesis of (S)-3(aminomethyl)-5-methylhexanoic acid, commonly known as pregabalin. Pregabalin is utilized in the treatment and prevention of seizure disorders, pain, and psychotic disorders.
Career Highlights
Justin K Weaver is currently employed at Pfizer Corporation, where he continues to advance his research in bioconversion technologies. His work at Pfizer has allowed him to collaborate with leading experts in the field, enhancing the impact of his inventions.
Collaborations
Some of Weaver's notable coworkers include Michael P Burns and John Wing Wong. Their collaborative efforts contribute to the innovative environment at Pfizer Corporation.
Conclusion
Justin K Weaver is a prominent inventor whose work in bioconversion technologies has the potential to significantly impact medical treatments. His contributions to the field are marked by his innovative patents and collaborations with esteemed colleagues.